WhatsApp 19 Julie 2021
Die persoon wat kla oor Gospel Mission... Wil jy nie eerder praat oor die sjebeens se drankverkope na ure en naweke as om oor die kerk te praat. Bemoeisiek is regtig 'n groot probleem. Sit jy jou masker op en bly tuis? Los die ander wat 'n honger het na die Lewende Woord. Viva Gospel Mission.
kykNET-verslag vanaand (14 Julie) gesê Sinopharm is die enigste entstof waar geen navorsing gedoen is vir veiligheid nie. Wat nou van ons Namibiërs wat albei dosisse geneem het?
Redakteur: Ons is nie bekend met die konteks of presies wat die stelling was waarna u verwys nie; moontlik dat navorsing nie plaaslik gedoen is nie?
Wat die WHO oor Sinopharm sê:
SAGE (the Strategic Advisory Group of Experts on Immunization) has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
Safety data are limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared to younger age groups can be anticipated, countries considering using this vaccine in persons older than 60 years should maintain active safety monitoring.
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%.
kykNET-verslag vanaand (14 Julie) gesê Sinopharm is die enigste entstof waar geen navorsing gedoen is vir veiligheid nie. Wat nou van ons Namibiërs wat albei dosisse geneem het?
Redakteur: Ons is nie bekend met die konteks of presies wat die stelling was waarna u verwys nie; moontlik dat navorsing nie plaaslik gedoen is nie?
Wat die WHO oor Sinopharm sê:
SAGE (the Strategic Advisory Group of Experts on Immunization) has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.
Safety data are limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared to younger age groups can be anticipated, countries considering using this vaccine in persons older than 60 years should maintain active safety monitoring.
A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%.
Kommentaar
Republikein
Geen kommentaar is op hierdie artikel gelaat nie